Patents by Inventor Huiyong Hu
Huiyong Hu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230223408Abstract: Provided are a CMOS structure, and fabrication methods of a FinFET CMOS, an FD CMOS and a GAA CMOS. The CMOS structure includes an nMOS and a pMOS, The nMOS includes a first channel region and a first gate electrode formed on a semiconductor substrate, and the pMOS includes a second channel region and a second gate electrode formed on the semiconductor substrate, where the first channel region and the second channel region are formed of semiconductor materials with the same conductivity type, and the first gate electrode and the second gate electrode are formed of the conductive materials with the same work function. This CMOS structure reduces the processing steps for fabricating the CMOS, thereby reducing the process complexity and the production cost, which is beneficial for improving the performance and reliability of CMOS and its integrated circuits.Type: ApplicationFiled: March 17, 2023Publication date: July 13, 2023Inventors: Huiyong HU, Liming WANG, Bin SHU, Bin WANG, Ningning ZHANG, Tian MIAO, Jian ZHANG, Lingyao MENG, Maolong YANG, Xinlong SHI, Heming ZHANG
-
Publication number: 20230133667Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: ApplicationFiled: October 18, 2022Publication date: May 4, 2023Inventors: Peter Andrew Smith, Tucker Curran Roberts, Robert I. Higuchi, Prasuna Paraselli, Michael F. T. Koehler, Jacob Bradley Schwarz, James John Crawford, Cuong Q. Ly, Emily J. Hanan, Huiyong Hu, Yongsheng Chen, Zhiyong Yu, Paul Colin Michael Winship, Calum MacCleod, Toby Blench
-
Publication number: 20230133817Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: ApplicationFiled: December 8, 2022Publication date: May 4, 2023Inventors: Yongsheng Chen, Peter Andrew Smith, Tuker Curran Roberts, Robert I. Higuchi, Prasuna Paraselli, Michael F.T Koehler, Jacob Bradley Schwarz, James John Crawford, Cuong Q. Ly, Emily J. Hanan, Huiyong Hu, Zhiyong Yu
-
Publication number: 20230127065Abstract: A concrete sandwich composite structure of an ultra-high performance concrete wrapped steel tube includes a steel arch, a plurality of connecting members and an ultra-high performance concrete layer.Type: ApplicationFiled: October 26, 2022Publication date: April 27, 2023Inventors: Pinghua Ning, Xiaogang Yue, Fei Guo, Huiyong Hu, Sheng Wang, Yu Zhou, Songtao Zhang, Jiongkun Zeng
-
Patent number: 11072635Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: GrantFiled: November 21, 2016Date of Patent: July 27, 2021Assignees: RQX Pharmaceuticals, Inc., Genentech, Inc.Inventors: Yongsheng Chen, Peter Andrew Smith, Tucker Curran Roberts, Robert I. Higuchi, Prasuna Paraselli, Michael F. T. Koehler, Jacob Bradley Schwarz, James John Crawford, Cuong Q. Ly, Huiyong Hu, Zhiyong Yu
-
Publication number: 20210198316Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: ApplicationFiled: August 13, 2019Publication date: July 1, 2021Inventors: Peter Andrew SMITH, Tucker Curran ROBERTS, Robert I. HIGUCHI, Prasuna PARASELLI, Michael F. T. KOEHLER, Jacob Bradley SCHWARZ, James John CRAWFORD, Cuong Q. LY, Emily J. HANAN, Huiyong HU, Yongsheng CHEN, Zhiyong YU, Paul Colin Michael WINSHIP, Calum McCleod, Toby Blench
-
Publication number: 20200239519Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: ApplicationFiled: November 21, 2016Publication date: July 30, 2020Inventors: Yongsheng CHEN, Peter Andrew SMITH, Tucker Curran ROBERTS, Robert I. HIGUCHI, Prasuna PARASELLI, Michael F. T. KOEHLER, Jacob Bradley SCHWARZ, James John CRAWFORD, Cuong Q. LY, Huiyong HU, Zhiyong YU
-
Publication number: 20200024309Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: ApplicationFiled: August 13, 2019Publication date: January 23, 2020Inventors: Peter Andrew SMITH, Tucker Curran ROBERTS, Robert I. HIGUCHI, Prasuna PARASELLI, Michael F. T. KOEHLER, Jacob Bradley SCHWARZ, James John CRAWFORD, Cuong Q. LY, Emily J. HANAN, Huiyong HU, Yongsheng CHEN, Zhiyong YU, Paul Colin Michael WINSHIP, Calum McCleod, Toby Blench
-
Patent number: 10392422Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: GrantFiled: May 19, 2015Date of Patent: August 27, 2019Assignees: RQX PHARMACEUTICALS, INC., GENENTECH, INC.Inventors: Tucker Curran Roberts, Peter Andrew Smith, Robert I. Higuchi, Prasuna Paraselli, Philippe Bergeron, Michael F. T. Koehler, Huiyong Hu, Jacob Bradley Schwarz, Cuong Ly, James John Crawford
-
Patent number: 10351595Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: GrantFiled: May 19, 2015Date of Patent: July 16, 2019Assignees: RQX PHARMACEUTICALS, INC., GENENTECH, INC.Inventors: Tucker Curran Roberts, Peter Andrew Smith, Robert I. Higuchi, Prasuna Paraselli, Philippe Bergeron, Michael F. T. Koehler, Huiyong Hu, Jacob Bradley Schwarz, Cuong Ly, James John Crawford
-
Publication number: 20180327367Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: ApplicationFiled: November 21, 2016Publication date: November 15, 2018Inventors: Yongsheng CHEN, Peter Andrew SMITH, Tucker Curran ROBERTS, Robert I. HIGUCHI, Prasuna PARASELLI, Michael F. T. KOEHLER, Jacob Bradley SCHWARZ, James John CRAWFORD, Cuong Q. LY, Emily J. HANAN, Huiyong HU, Zhiyong YU
-
Patent number: 9850239Abstract: Pyrazolo[3,4-c]pyridine compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: GrantFiled: February 16, 2016Date of Patent: December 26, 2017Assignee: Genentech, Inc.Inventors: Steven Do, Huiyong Hu, Aleksandr Kolesnikov, Wendy Lee, Vickie Hsiao-Wei Tsui, Xiaojing Wang, Zhaoyang Wen
-
Publication number: 20170088582Abstract: Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of bacterial type 1 signal peptidase (SpsB), an essential protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.Type: ApplicationFiled: May 19, 2015Publication date: March 30, 2017Applicants: RQX PHARMACEUTICALS, INC., GENENTECH, INC.Inventors: Tucker Curran ROBERTS, Peter Andrew SMITH, Robert I. HIGUCHI, Prasuna PARASELLI, Philippe BERGERON, Michael F.T. KOEHLER, Huiyong HU, Jacob Bradley SCHWARZ, Cuong LY, James CRAWFORD
-
Patent number: 9434725Abstract: 5-Azaindazole compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: GrantFiled: June 26, 2013Date of Patent: September 6, 2016Assignee: F. HOFFMANN-LA ROCHE AGInventors: Steven Do, Huiyong Hu, Aleksandr Kolesnikov, Vickie H. Tsui, Xiaojing Wang
-
Publication number: 20160159797Abstract: Pyrazolo[3,4-c]pyridine compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: ApplicationFiled: February 16, 2016Publication date: June 9, 2016Applicant: Genentech, Inc.Inventors: Steven Do, Huiyong Hu, Aleksandr Kolesnikov, Wendy Lee, Vickie Hsiao-Wei Tsui, Xiaojing Wang, Zhaoyang Wen
-
Patent number: 9260425Abstract: Pyrazolo[3,4-c]pyridine compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: GrantFiled: August 10, 2012Date of Patent: February 16, 2016Assignee: Genetech, Inc.Inventors: Steven Do, Huiyong Hu, Aleksandr Kolesnikov, Wendy Lee, Vickie H. Tsui, Xiaojing Wang, Zhaoyang Wen
-
Publication number: 20140005168Abstract: 5-Azaindazole compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: ApplicationFiled: June 26, 2013Publication date: January 2, 2014Inventors: Steven Do, Huiyong Hu, Aleksandr Kolesnikov, Vickie H. Tsui, Xiaojing Wang
-
Publication number: 20130039906Abstract: Pyrazolo[3,4-c]pyridine compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R1 and R2 are as defined herein, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.Type: ApplicationFiled: August 10, 2012Publication date: February 14, 2013Inventors: Steven Do, Huiyong Hu, Aleksandr Kolesnikov, Wendy Lee, Vickie H. Tsui, Xiaojing Wang, Zhaoyang Wen
-
Publication number: 20100261706Abstract: Provided herein are tetracyclic 1H-indeno[1,2-b]pyridine-2(5H)-one analogs and derivatives, compositions comprising an effective amount of a tetracyclic 1H-indeno[1,2-b]pyridine-2(5H)-one analog and/or derivative and methods for treating or preventing an inflammatory disease, a reperfusion injury, diabetes mellitus, a diabetic complication, a reoxygenation injury resulting from organ transplantation, an ischemic condition, a neurodegenerative disease, renal failure, a vascular disease, a cardiovascular disease, an ocular or opthalmologic disease, cancer, a complication of prematurity, cardiomyopathy, retinopathy, nephropathy, contrast induced nephropathy, neuropathy, erectile dysfunction or urinary incontinence, comprising administering to a subject in need thereof an effective amount of a tetracyclic 1H-indeno[1,2-b]pyridine-2(5H)-one analog or derivative.Type: ApplicationFiled: December 8, 2009Publication date: October 14, 2010Applicant: INOTEK PHARMACEUTICALS CORPORATIONInventors: Prakash JAGTAP, Duy-Phong Pham-Huu, Frederick COHEN, Huiyong HU, Xiaojing WANG
-
Publication number: 20070287699Abstract: Compounds are provided having utility for the treatment of viral infections, particularly HCV.Type: ApplicationFiled: April 30, 2007Publication date: December 13, 2007Applicant: ViroBay, Inc.Inventors: Dange Kumar, Roopa Rai, Wendy Young, Huiyong Hu, Jennifer Riggs, Tony Ton, Michael Green, Barry Hart, Kenneth Brameld, Jeffrey Dener